MDT

86.05

+0.2%↑

A

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

MDT

86.05

+0.2%↑

A

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

MDT

86.05

+0.2%↑

A

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

MDT

86.05

+0.2%↑

A

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

MDT

86.05

+0.2%↑

A

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

Search

Cytek Biosciences Inc

Avatud

SektorTervishoid

4.58 -0.87

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.33

Max

4.64

Põhinäitajad

By Trading Economics

Sissetulek

-39M

-44M

Müük

9.8M

62M

Kasumimarginaal

-70.929

Töötajad

702

EBITDA

4M

-263K

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+43.02% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-8.6M

553M

Eelmine avamishind

5.45

Eelmine sulgemishind

4.58

Uudiste sentiment

By Acuity

50%

50%

163 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. apr 2026, 22:56 UTC

Uudisväärsed sündmused

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1. apr 2026, 20:50 UTC

Omandamised, ülevõtmised, äriostud

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1. apr 2026, 23:55 UTC

Market Talk

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1. apr 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1. apr 2026, 23:23 UTC

Uudisväärsed sündmused

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1. apr 2026, 23:07 UTC

Tulu

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1. apr 2026, 23:02 UTC

Uudisväärsed sündmused

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1. apr 2026, 22:39 UTC

Tulu

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1. apr 2026, 22:08 UTC

Market Talk

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1. apr 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1. apr 2026, 21:31 UTC

Uudisväärsed sündmused

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. apr 2026, 20:38 UTC

Tulu

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1. apr 2026, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1. apr 2026, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1. apr 2026, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1. apr 2026, 20:13 UTC

Omandamised, ülevõtmised, äriostud

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1. apr 2026, 20:07 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1. apr 2026, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

43.02% tõus

12 kuu keskmine prognoos

Keskmine 6.25 USD  43.02%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

163 / 349 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat